Rafarma Pharmaceuticals, Inc. (RAFA)
| Previous close | 0.0644 |
| Open | 0.0600 |
| Bid | 0.0570 x 0 |
| Ask | 0.0670 x 0 |
| Day's range | 0.0600 - 0.0600 |
| 52-week range | 0.0330 - 0.4270 |
| Volume | |
| Avg. volume | 14,448 |
| Market cap | 5.266M |
| Beta (5Y monthly) | 1.37 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Rafarma pharmaceutical updates: registration of Rafarma microspheres in South Korea
Sheridan, Wyoming, USA, July 04, 2024 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA) - Rafarma Pharmaceuticals is pleased to announce its participation in the scientific conference on radioembolization using Yttrium 90 microspheres for the treatment of cancer at Severance Hospital in Seoul, South Korea. It is one of the largest university hospitals in South Korea and is of strategic importance to the country. Currently, procedure is underway to register Yttrium 90 microspheres produced
- GlobeNewswire
Rafarma pharmaceutical updates: creation of a joint research and production enterprise in Busan (South Korea) between Rafarma and the Korean pharmaceutical company Woods Medical Care
Sheridan, Wyoming, USA, July 03, 2024 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA) - Rafarma Pharmaceuticals is pleased to announce the signing of a preliminary agreement to establish a joint industrial venture in Busan Technology Park (South Korea) as the Dongnam Industrial Park of Radiological & Medical Sciences. The partners in the venture are Rafarma and the Korean pharmaceutical company Woods Medical Care. Woods Medical Care, Inc. was established to grow into a global pharmaceuti
- GlobeNewswire
Rafarma pharmaceutical updates: agreements with Shri Lanka pharmaceutical company Kelun Lifesciences (Pvt) Ltd and El Salvador University
Wyoming, USA, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA) - We are pleased to announce that Rapharma and its CEO Raivo Unt have entered into a preliminary agreement with Kelun Lifesciences (Pvt) Ltd, a pharmaceutical company based in Sri Lanka, on 17 November 2023. It is Sri Lanka's first and only pharmaceutical manufacturing facility for sterile liquid injections and infusions. The headquarters of the company is based in Kandy on the island of Sri Lanka. Thus, the inte
